India tightens drug safety rules after deadly cough syrup scandals

India tightens drug safety rules after deadly cough syrup scandals

CDSCO Makes Pharmacovigilance Compliance Mandatory For Pharma Companies To Strengthen Drug Safety Monitoring

India tightens drug safety rules after deadly cough syrup scandals

India’s drug regulator has tightened rules on pharmacovigilance and drug safety monitoring. The Central Drugs Standard Control Organisation (CDSCO) issued a fresh directive requiring all licence holders to set up systems for tracking adverse drug reactions (ADRs). This move follows concerns over contaminated medicines linked to child deaths abroad and aims to strengthen oversight of pharmaceutical products after they reach the market. The CDSCO has reminded manufacturers, importers, and other stakeholders of their legal duty to maintain robust pharmacovigilance systems. These systems must collect, process, and report any adverse reactions tied to their drugs. Regulatory officers from the CDSCO, State Licensing Authorities (SLA), and Union Territory administrations will now check compliance during routine inspections.

The directive gains urgency after recent cases of toxic cough syrups causing fatalities in children outside India. Such incidents exposed gaps in quality control and post-marketing surveillance, pushing regulators to enforce stricter monitoring. The updated requirements align with global standards set by the World Health Organization (WHO), following amendments to Schedule M, which governs Good Manufacturing Practices (GMP) in India. Health experts see the new rules as a key measure to detect safety risks early. A well-functioning pharmacovigilance system allows regulators to spot harmful effects sooner, recall unsafe products, and prevent wider health crises. The changes also reinforce accountability for drugmakers, ensuring they track their products’ performance beyond initial approvals.

The CDSCO’s latest circular reinforces the need for continuous monitoring of drug safety. Companies must now ensure their pharmacovigilance systems meet the updated standards or face regulatory action. Inspections will verify adherence, reducing the risk of unsafe medicines reaching patients.

Neueste Nachrichten